{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(1)"],"submitter":["Sato K"],"funding":["University of Queensland","“la Caixa” Foundation","Wesley Medical Research","The Health Research Board of Ireland","European Union’s research and innovation programme","Prince Charles Hospital Foundation","Biomedicine international training research programme for excellent clinician-scientists","Wellcome Trust"],"pubmed_abstract":["<h4>Background</h4>The influence of renin-angiotensin-aldosterone system (RAAS) inhibitors on the critically ill COVID-19 patients with pre-existing hypertension remains uncertain. This study examined the impact of previous use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the critically ill COVID-19 patients.<h4>Methods</h4>Data from an international, prospective, observational cohort study involving 354 hospitals spanning 54 countries were included. A cohort of 737 COVID-19 patients with pre-existing hypertension admitted to intensive care units (ICUs) in 2020 were targeted. Multi-state survival analysis was performed to evaluate in-hospital mortality and hospital length of stay up to 90 days following ICU admission.<h4>Results</h4>A total "],"journal":["BMC cardiovascular disorders"],"pagination":["123"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8942148"],"repository":["biostudies-literature"],"pubmed_title":["Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study."],"pmcid":["PMC8942148"],"pubmed_authors":["Grasselli G","Ichiba S","Murthy S","Laffey J","White N","Fanning JP","Obonyo N","Ohshimo S","Fraser JF","Ng PY","Arora RC","Bartlett R","Worku ET","Fan E","Ogino M","Hodgson C","May M","Nichol A","Chiumello D","Torres A","Elhazmi A","Appadurai V","Marwali E","Yang I","Ciullo A","Suen JY","Luna C","Burrell A","COVID-19 Critical Care Consortium Investigators","Brodie D","Juzar DA","Bassi GL","Sato K","Dip G","Yamashita MH","Helms L","Dalton HJ"],"additional_accession":[]},"is_claimable":false,"name":"Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.","description":"<h4>Background</h4>The influence of renin-angiotensin-aldosterone system (RAAS) inhibitors on the critically ill COVID-19 patients with pre-existing hypertension remains uncertain. This study examined the impact of previous use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the critically ill COVID-19 patients.<h4>Methods</h4>Data from an international, prospective, observational cohort study involving 354 hospitals spanning 54 countries were included. A cohort of 737 COVID-19 patients with pre-existing hypertension admitted to intensive care units (ICUs) in 2020 were targeted. Multi-state survival analysis was performed to evaluate in-hospital mortality and hospital length of stay up to 90 days following ICU admission.<h4>Results</h4>A total ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T14:57:14.992Z","creation":"2024-11-20T05:53:21.706Z"},"accession":"S-EPMC8942148","cross_references":{"pubmed":["35321649"],"doi":["10.1186/s12872-022-02565-1"]}}